Health and Fitness Health and Fitness
Fri, February 13, 2009
[ 03:00 AM ] - Market Wire
Electro-Optical Sciences, Inc.: Electro-Optical S .. op-Line Results From Landmark MelaFind(R) Pivotal
Thu, February 12, 2009
[ 02:41 PM ] - Market Wire
Osiris Announces Fourth Quarter and Full Year 2008 Financial Results Conference Call
[ 01:29 PM ] - Market Wire
Cubist Pharmaceuticals Announces Start of First-i .. nvestigational New Drug for Clostridium difficile
[ 01:15 PM ] - Market Wire
Hansen Medical, Inc.: Hansen Medical Reports 2008 Fourth Quarter and Year-End Results
[ 01:05 PM ] - Market Wire
Theravance, Inc.: Theravance Reports Fourth Quarter and Full Year 2008 Results
[ 01:00 PM ] - Market Wire
Kindred Healthcare?s Year-End Conference Call Scheduled for February 20
[ 12:30 PM ] - Market Wire
Noven to Present at Roth 21ST Annual Growth Stock Conference
[ 12:30 PM ] - Market Wire
University Clinic Heidelberg Explores Advanced TomoTherapy® Delivery Technique
[ 12:15 PM ] - Market Wire
LabCorp is the First National Commercial Lab to O .. che?s COBAS® AmpliPrep/COBAS® TaqMan® HCV Test
[ 12:05 PM ] - Market Wire
Oculus Innovative Sciences Reports Third Quarter .. th a $2.6 Million Reduction in Operating Expenses
[ 12:05 PM ] - Market Wire
Targacept Reports Fourth Quarter and 2008 Financial Results
[ 12:05 PM ] - Market Wire
XenoPort Reports Fourth Quarter and Year-End 2008 Financial Results
[ 12:05 PM ] - Market Wire
Ligand Pharmaceuticals and The Rockefeller Univer .. ity Enter Settlement Agreement and Mutual Release
[ 12:05 PM ] - Market Wire
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results
[ 12:00 PM ] - Market Wire
Cerus to Release Fourth Quarter and Year End 2008 Financial Results on February 26, 2009
[ 11:15 AM ] - Market Wire
Biovail Announces Fourth-Quarter 2008 Earnings Release, Conference-Call Details
[ 10:51 AM ] - Market Wire
Clinical Data, Inc. To Present at the Roth 21st Annual OC Growth Stock Conference
[ 10:30 AM ] - Market Wire
I-Flow Will Present at the Roth Capital Partners .. nce Wednesday, February 18, 2009 at 4:00 p.m. PST
[ 09:12 AM ] - Market Wire
InSight Health Services Holdings Corp. to Host Second Quarter Fiscal 2009 Results Conference Call
[ 09:00 AM ] - Market Wire
American Shared Hospital Services to Develop Prot .. iation Therapy Facility in San Francisco Bay Area
[ 07:33 AM ] - Market Wire
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
[ 06:23 AM ] - Market Wire
Samenvatting: Emergent BioSolutions maakt bekend .. traxvaccin) marktautorisatie in India heeft ontva
[ 06:09 AM ] - Market Wire
Trinity Biotech: Trinity Biotech Announces Appoin .. of James D. Merselis as a Non-Executive Director
[ 05:15 AM ] - Market Wire
AVI BioPharma, Inc.: AVI BioPharma, Inc. Appoints Chief Medical Officer
[ 05:00 AM ] - Market Wire
Shareholder Group Led by Adrenalina Announces Nom .. didates for Election to the Pacific Sunwear Board
[ 04:00 AM ] - Market Wire
Curis Announces Genentech?s Initiation of Pivotal .. rial of GDC-0449 in Advanced Basal Cell Carcinoma
[ 04:00 AM ] - Market Wire
Hythiam Announces Presentation at the Roth 21st Annual OC Growth Stock Conference
[ 04:00 AM ] - Market Wire
Alnylam and Collaborators Present Data from Multi .. and Clinical Programs at RNAi Keystone Symposium
[ 03:30 AM ] - Market Wire
ARIAD Reports Financial Guidance for 2009 and Fourth Quarter and Year-End 2008 Financial Results
[ 03:30 AM ] - Market Wire
La Jolla Pharmaceutical Company Announces Negativ .. Efficacy Analysis for Riquent Phase 3 ASPEN Trial

La Jolla Pharmaceutical Company Announces Negative Results of Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial


Published on 2009-02-12 04:54:27, Last Modified on 2009-02-12 04:54:47 - Market Wire
  Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--La Jolla Pharmaceutical Company (Nasdaq:LJPC) announced today that the Independent Data Monitoring Board for the Riquent® Phase 3 ASPEN study has informed the Company that they have completed the first interim efficacy analysis and determined that continuing the study is futile. The Company has decided to stop the study, unblind the data and evaluate the results. The Company expects to provide additional guidance on its strategic options going forward in the near future.

Contributing Sources